POWERFUL COLLABORATION
Learn more about the MMRC’s efforts to bring new treatments to patients – faster. EXPANDED ACCESS PROGRAMThe MMRF teams up with Onyx Pharmaceuticals to bring carfilzomib to patients with advanced multiple myeloma through C-MAP. Click here to see if you are eligible* for this new treatment option. IN THE SPOTLIGHTSubcutaneous Velcade Approved!The FDA has approved the subcutaneous administration of Velcade - encouraging for patients due to the lower rate of neuropathy. Read Millennium's press release. News from the ASH Annual MeetingUpdates from ASH Webcast |
LANDMARK RESEARCHThe MMRF is excited to announce its newest initiative, the MMRF CoMMpass℠ (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) Study. This long term study will use principles of personalized medicine to generate hypotheses that may lead to new treatments for multiple myeloma, ultimately charting a course to a cure. NEWSFebruary 10, 2012: 35th Annual Empire State Building Run-Up Powered by the MMRF Raises Funds for Multiple Myeloma Research Foundation (MMRF)January 23, 2012: FDA Approves Subcutaneous Administration of VELCADE® In All Approved IndicationsJanuary 23, 2012: Multiple Myeloma Research Foundation (MMRF) Awarded with Highest Rating from Charity Navigator for 9th Consecutive YearJanuary 19, 2012: The Multiple Myeloma Research Foundation (MMRF) Releases White Paper Outlining the Increasingly Important Role of Non-Profit Organizations in Drug Development |
EVENTSJoin an MMRF event or start your own event. Together we can make a real difference for myeloma patients. Chicago Awards Dinner
MMRF Endurance EventsJoin the MMRF at one of 20 world class Endurance Events, from marathons to cycling events to triathlons. Check out the opportunities in 2012, including Great Races like the Empire State Building Run-Up. Shop the MMRF StoreHonor yourself or someone special while supporting the MMRF when you shop the MMRF Store. |



Join us for the 11th annual 
